Portugal now part of MRA with FDA
Recommendation
28/29 October 2025
Hamburg, Germany
A CAPA Workshop on Successful Failure Investigation
Register now for ECA's GMP Newsletter
After a positive assessment, the US Food and Drug Administration (FDA) has approved Portugal to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
The total number of countries accepted by the FDA is now 15: Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Other EU member states will be added as their evaluation is completed by the US. According to a previous EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Source: EMA Press Release entitled "Portugal to also benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published